PMID- 20657886
OWN - NLM
STAT- MEDLINE
DCOM- 20101007
LR  - 20191111
IS  - 0048-7449 (Print)
IS  - 0048-7449 (Linking)
VI  - 62
IP  - 2
DP  - 2010 Apr-Jun
TI  - Safety of rituximab in rheumatoid arthritis.
PG  - 101-6
AB  - Rheumatoid arthritis (RA) is a chronic disease that requires long-term 
      administration of immunomodulatory drugs with a greater risk of side effects like 
      malignancies, serious infections and cardiovascular diseases. Furthermore, 
      patients with RA are more prone than the general population to these 
      manifestations. Safety of rituximab has been evaluated in the short-term (6 
      months) and in the medium-term (up to 10 years) in patients who had been 
      previously treated with antagonists of tumor necrosis factor (a-TNF) and/or with 
      methotrexate (MTX) and in patients who were not. Data obtained from clinical 
      trials demonstrated that rituximab is well tolerated either after a single course 
      or after multiple courses. The overall rate of adverse events (AEs) was stable 
      after the first three courses. The most frequent adverse event was 
      infusion-related reactions (IRR). Serious infections did not increase after 
      multiple courses. Data from "real life" confirm that treatment with rituximab is 
      well tolerated.
FAU - Covelli, M
AU  - Covelli M
AD  - Azienda Ospedaliera Universitaria Policlinico, DIMIMP-Sezione di Reumatologia, 
      Universita degli Studi di Bari, Italy. michelecovelli@virgilio.it
FAU - Sarzi-Puttini, P
AU  - Sarzi-Puttini P
FAU - Atzeni, F
AU  - Atzeni F
FAU - Macchioni, P
AU  - Macchioni P
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Italy
TA  - Reumatismo
JT  - Reumatismo
JID - 0401302
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 0 (Antirheumatic Agents)
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
MH  - Antibodies, Monoclonal/adverse effects/*therapeutic use
MH  - Antibodies, Monoclonal, Murine-Derived
MH  - Antirheumatic Agents/adverse effects/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Rituximab
MH  - Treatment Outcome
RF  - 23
EDAT- 2010/07/27 06:00
MHDA- 2010/10/12 06:00
CRDT- 2010/07/27 06:00
PHST- 2010/07/27 06:00 [entrez]
PHST- 2010/07/27 06:00 [pubmed]
PHST- 2010/10/12 06:00 [medline]
AID - 10.4081/reumatismo.2010.101 [doi]
PST - ppublish
SO  - Reumatismo. 2010 Apr-Jun;62(2):101-6. doi: 10.4081/reumatismo.2010.101.